Sumitovant Biopharma Completes Acquisition of Myovant Sciences
Sumitovant Biopharma completed its acquisition of Myovant Sciences originally announced Oct. 23, 2022. Sumitovant has acquired all outstanding shares of Myovant not already owned by Sumitovant in an all-cash deal with a total transaction value of approximately $1.7 billion.
March 13, 2023
David Marek | Goldman Sachs | Hiroshi Nomura | J.P. Morgan Securities | Myovant Sciences | Myrtle Potter | Skadden Arps Slate Meagher & Flom | Sullivan & Cromwell | Sumitomo Pharma | Sumitovant Biopharma
Ian Koplin